Conceptual Entity
Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results
Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials
Biogen Expands Leqembi Field Force and Launches Omnichannel Campaigns for Next Phase
Biogen, Leqembi, field force, expansion, omnichannel campaigns, launch phase, Alzheimer’s treatment
Eli Lilly Anticipates Zepbound Label Expansion Following Positive Phase III Sleep Apnea Study Results
Eli Lilly, Zepbound (tirzepatide), Phase III Sleep Apnea Study, SURMOUNT-OSA, Obstructive Sleep Apnea (OSA), Label Expansion, Fast Track Designation, Symptom Improvement
FDA Oncology Chief Emphasizes Equitable Standards in Confirmatory Trial Rejections at AACR24
AACR24, FDA Oncology Chief, Richard Pazdur, Confirmatory Trial Rejection, Level Playing Field, Project
Acorda Therapeutics Concludes $185M Asset Sale with Merz amid Bankruptcy Filing Following Disappointing Sales
Acorda Therapeutics, $185M asset sale, Merz, Bankruptcy filing, Years of disappointing sales, Multiple Sclerosis drug Fampyra, Biogen returns ex-US rights, Generic competition, Declining sales, Neurological diseases
FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment
Overall Survival, Combined, cisplatin, Opdivo
Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership
Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million